Drug Insights

Ritlecitinib - Dual Inhibitor of JAK3/TEC

26 July 2023
3 min read

Ritlecitinib, trade name LITFULO, is a small molecule drug targeting JAK3 and TEC (see Figure 2-9 for molecular structure). This drug is a once-daily oral treatment, developed by Pfizer Inc. On June 23, 2023, the Type 1 new drug application submitted has been approved by the FDA for treatment of individuals 12 years of age and older with severe alopecia areata. 

图示, 工程绘图

描述已自动生成

According to Synapse, the drug involves a total of 8 indications, including Alopecia Areata, Nonsegmental vitiligo, Cutaneous T-Cell Lymphoma, Celiac Disease, Crohn Disease, Colitis, Ulcerative, Rheumatoid and Kidney Diseases. The Phase I clinical trial on renal insufficiency was initiated in August 2019, but was terminated due to extensive delays in COVID-19. These indications have all entered the clinical trial stage. The research progress on alopecia areata has not only been approved in the United States, but also has submitted listing applications in China, Europe, Japan, and the UK. For more detailed information on R&D status, core patents, analysis, etc, please click on the image link below.

图表

中度可信度描述已自动生成

Mechanism of Action

It is the first and only treatment approved by the FDA for adolescents (12+) with severe alopecia areata.Ritlecitinib irreversibly inhibits Janus kinase 3 (JAK3) and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family by blocking the adenosine triphosphate (ATP) binding site. In cellular settings, ritlecitinib inhibits cytokine induced STAT phosphorylation mediated by JAK3-dependent receptors. Additionally, ritlecitinib inhibits signaling of immune receptors dependent on TEC kinase family members. The relevance of inhibition of specific JAK or TEC family enzymes to therapeutic effectiveness is not currently known. 

Efficacy and safety

The FDA approval was based on results(Figure 2-10) of clinical trials in alopecia areata. The ALLEGRO Phase 2b/3 trial (NCT03732807) , which enrolled 718 patients with 50% or more scalp hair loss as measured by the Severity of Alopecia Tool (SALT), evaluated the efficacy and safety of LITFULO at 118 sites in 18 countries. In this pivotal study, 23% of patients treated with LITFULO 50 mg had 80% or more scalp hair coverage (SALT20) after six months compared to 1.6% with placebo. The efficacy and safety of LITFULO were consistent between adolescents (12 through 17 years of age) and adults (18 years of age and older). 

The most common adverse events (AEs) reported in at least 4% of patients with LITFULO include headache (10.8%), diarrhea (10%), acne (6.2%), rash (5.4%), and urticaria (4.6%). 

Competitive Landscape

表格

描述已自动生成

According to Synapse, at present, this drug is the only one that targets both JAK3 and TEC simultaneously. 

Sequence-based drug design with AI: A Paradigm Shift in Drug Discovery
Advanced Tech.
5 min read
Sequence-based drug design with AI: A Paradigm Shift in Drug Discovery
26 July 2023
These limitations include the absence of high-resolution structures for numerous proteins, the challenge of accurately predicting active sites, defining binding pockets for novel targets with multiple domains, and anticipating allosteric sites.
Read →
Roche introduces Alnylam's hypertension RNAi therapy, Zilebesiran, with a potential transaction value of up to 2.8 billion dollars
Latest Hotspot
3 min read
Roche introduces Alnylam's hypertension RNAi therapy, Zilebesiran, with a potential transaction value of up to 2.8 billion dollars
26 July 2023
On July 24, 2023, Alnylam announced that it has reached a strategic agreement with Roche to develop and commercialize Zilebesiran, Alnylam's RNAi therapeutic drug for the treatment of hypertension.
Read →
CanSino's Herpes Zoster vaccine CS-2032 has been approved for clinical use in Canada
Latest Hotspot
2 min read
CanSino's Herpes Zoster vaccine CS-2032 has been approved for clinical use in Canada
26 July 2023
On July 23, CanSino Biologics announced that its recombinant shingles vaccine CS-2032, developed in collaboration with Vaccitech, has received clinical trial approval from Health Canada.
Read →
An Overview of Organon 's 125 Drug Pipelines ——Top 50 Pharmaceutical Companies R&D Progress
R&D Pipeline
2 min read
An Overview of Organon 's 125 Drug Pipelines ——Top 50 Pharmaceutical Companies R&D Progress
26 July 2023
Organon & Co. is a pharmaceutical organization founded in 2020 and based in Noord-Brabant, Netherlands. The company operates in the field of biomedicine and focuses on the development of drugs for various therapeutic areas.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.